SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-24-075631
Filing Date
2024-06-20
Accepted
2024-06-20 16:30:03
Documents
2
Period of Report
2024-06-18

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3801
2 EX-24.POA inzy-ex24_poa.htm EX-24.POA 27636
  Complete submission text file 0000950170-24-075631.txt   32976
Mailing Address C/O MEDIMMUNE, INC. ONE MEDIMMUNE WAY GAITHERSBURG MD 20878
Business Address
Mathers Edward T (Reporting) CIK: 0001328625 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39397 | Film No.: 241056687

Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Issuer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)